Tolérance du baricitinib dans le traitement de la dermatite atopique chez les patients pédiatriques âgés de 2 ans à 18 ans
M. Ikeda(Okayama University), C. Jacobzone Leveque(Centre Hospitalier de Bretagne Sud), Marieke M.B. Seyger(Radboud University Nijmegen), Lawrence F. Eichenfield(University of California San Diego), Andreas Wollenberg(University Hospital Augsburg), Christopher Yang(California Institute of Technology), Danting Zhu(Eli Lilly (United States)), Ajay Prakash(Eli Lilly (United States)), Wen‐Shuo Wu(University of San Francisco), M. Pontes(Eli Lilly (United States)), Amy S. Paller(Northwestern University)
Cited by 0
Related Papers
Guidelines for the Diagnosis and Management of Food Allergy in the United States: Summary of the NIAID-Sponsored Expert Panel Report
|Journal of Allergy and Clinical Immunology|2010|2.3k
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
|New England Journal of Medicine|2016|2.1k
Guidelines of care for the management of atopic dermatitis
|Journal of the American Academy of Dermatology|2013|1.3k
Guidelines of care for the management of atopic dermatitis
|Journal of the American Academy of Dermatology|2014|1.2k
Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics
|Journal of the American Academy of Dermatology|2019|917